O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202

• DOI: 10.1016/j.annonc.2022.04.443
• Publication Date: 2022-07-02T15:31:13Z
• Authors: A. Vogel; V. Sahai; A. Hollebecque; G. Vaccaro; D. Melisi; R. Al-Rajabi; S. Paulson; M. Borad; D. Gallinson; A. Murphy; D. Oh; E. Dotan; D. Catenacci; E. Van Cutsem; C. Lihou; H. Zhen; L. Veronese; G. Abou-Alfa
• Keywords: Clinical endpoint